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Summary 
Background and purpose: The 5-HT7 receptor is a G-protein coupled receptor that is the 
target of a broad range of antidepressant and antipsychotic drugs. Various studies have 
demonstrated an ability of the 5-HT7 receptor to modulate glutamatergic neurotransmission 
and cognitive processes although the potential impact upon AMPA receptors has not been 
investigated directly. The purpose of the present study was to investigate a direct modulation 
of the GluA1 AMPA receptor subunit and determine how this might influence AMPA 
receptor function.   
Experimental approach: The influence of pharmacological manipulation of the 5-HT7 
receptor system upon phosphorylation of GluA1 subunits was assessed by western blotting of 
fractionated proteins from hippocampal neurones in culture (or proteins resident at the 
neurone surface) and the functional impact assessed by electrophysiological recordings in rat 
hippocampus in vitro and in vivo. 
Key results: 5-HT7 receptor activation increased cAMP and relative pCREB levels in 
cultures of rat hippocampal neurones along with an increase in phosphorylation (Ser845) of 
the GluA1 AMPA receptor subunit evident in whole neurone extracts and within the neurone 
surface compartment. Electrophysiological recordings in rat hippocampus demonstrated a 5-
HT7 receptor-mediated increase in AMPA receptor-mediated neurotransmission in vitro and 
in vivo. 
Conclusions and implications: The 5-HT7 receptor-mediated phosphorylation of the GluA1 
AMPA receptor provides a molecular mechanism consistent with the 5-HT7 receptor-
mediated increase in AMPA receptor-mediated neurotransmission. 
Abbreviations 
A, adenine; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; C, cytosine; 
CaMKII, Ca
2+
/calmodulin-dependent protein kinase II; cAMP, cyclic adenosine 
monophosphate; cDNA, complementary deoxyribonucleic acid; CREB, cAMP response 
element-binding protein; 5-CT, 5-carboxamidotryptamine; DAPI, 4',6-diamidino-2-
phenylindole; DMSO, dimethyl sulfoxide; DNA, deoxyribonucleic acid; dNTPs, 
deoxynucleotides; EDTA, ethylenediaminetetraacetic acid; EGTA, ethylene glycol tetraacetic 
acid; ELISA, enzyme-linked immunosorbent assay; EPSCs, excitatory post-synaptic currents; 
FBS, foetal bovine serum; FSK, forskolin; G, guanine; GABA, gamma-aminobutyric acid; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GFAP, glial fibrillary acidic protein; 
HBSS, Hank’s balanced salt solution; HRP, horseradish peroxidase; 5-HT, 5-
hydroxytryptamine; IBMX, 3-isobutyl-1-methylxanthine; KO, knock-out; LTP, long-term 
potentiation; MAP, mitogen activated protein; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-
benzo[f]quinoxaline-2,3-dione; NMDA, N-methyl-d-aspartate; PBS, phosphate buffered 
saline; PCR, polymerase chain reaction; pCREB, phosphorylated cAMP response element-
binding protein; PDE, phosphodiesterase; PKA, protein kinase A; PVDF, polyvinylidene 
difluoride; RNA, ribonucleic acid; RT, reverse transcription; SDS-PAGE, sodium dodecyl 
sulfate polyacrylamide gel electrophoresis; Ser, serine; T, thymine; TAE, Tris acetate EDTA; 
TTX, tetrodotoxin.    
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Introduction 
The 5-HT7 receptor has been cloned from various species and is a member of the G-protein 
coupled receptor superfamily (Hoyer et al., 1994; Alexander et al., 2013). The 5-HT7 receptor 
signals via an increase in cAMP production as well as various other pathways (e.g. Shen et 
al., 1993; for review see Gellynck et al., 2013) and is the focus of various projects to identify 
novel therapeutics to treat conditions such as depression, sleep disorders and cognitive 
deficits (e.g. Mnie-Filali et al., 2007). Further clinical interest in the 5-HT7 receptor arises 
from a broad range of antidepressant and antipsychotic drugs displaying relatively high 
affinity for the receptor (Roth et al., 1994). Further, two non-selective 5-HT7 receptor 
antagonists have recently received marketing authorisation for the treatment of psychiatric 
conditions: lurasidone and vortioxetine (Fountoulakis et al., 2015; Sanchez et al., 2015). 
Expression of the 5-HT7 receptor is apparent throughout the body with notable expression in 
the brain and spinal cord, vascular system and gastrointestinal tract (Waeber and Moskowitz, 
1995; Gustafson et al., 1996; Stowe and Barnes, 1998; Neumaier et al., 2001). Within the 
brain there is prominent expression within the hippocampus (Waeber and Moskowitz, 1995; 
Gustafson et al., 1996; Neumaier et al., 2001; Mengod et al., 2010), where homodimerisation 
and heterodimerisation with the 5-HT1A receptor may be relevant (Renner et al., 2012). At the 
cellular level within the hippocampus, expression in glutamatergic pyramidal neurones is 
evident (Neumaier et al., 2001), which is consistent with a number of independent studies 
demonstrating that the 5-HT7 receptor mediates excitation of glutamatergic pyramidal 
neurones and associated network activity (Bacon and Beck, 2000; Bickmeyer et al., 2002; 
Gill et al., 2002; Tokarski et al., 2003; 2005; Costa et al., 2012). Such neurophysiological 
actions may underlie the improvement in cognitive performance following 5-HT7 receptor 
activation (Meneses, 2004; Perez-Garcia and Meneses, 2005; Eriksson et al., 2008; Freret et 
al., 2014), which is consistent with the reduced cognitive performance following inhibition of 
5-HT7 receptor function by pharmacological antagonism or genetic manipulation (Meneses, 
2004; Ballaz et al., 2007; Sarkisyan and Hedlund, 2009; Freret et al., 2014; but see Horisawa 
et al., 2011 and Waters et al., 2012). However, some types of memory deficit are improved 
by 5-HT7 receptor antagonists (McLean et al., 2009; Bonaventure et al., 2011; Nikiforuk et 
al., 2013), which may be a consequence of different neurochemical mechanisms 
(Bonaventure et al., 2011) or biased signalling; this is consistent with the beneficial effects of 
some non-selective 5-HT7 receptor antagonists used to treat psychiatric conditions (e.g. 
Horiguchi et al., 2011).  
In terms of a molecular mechanism by which the 5-HT7 receptor might drive neuronal 
excitation in the hippocampus, recent evidence demonstrates that the 5-HT7 receptor mediates 
phosphorylation of NMDA glutamate receptors with a consequential increase in NMDA 
receptor signalling (Vasefi et al., 2013). Consistent with these findings, 5-HT7 receptor KO 
mice display reduced long term potentiation in the hippocampus (Roberts et al., 2004). It 
should be noted, however, that 5-HT7 receptor KO mice also display impaired contextual fear 
conditioning - a hippocampus-dependent phenomenon - but no deficit in spatial learning 
(Roberts et al., 2004), which implicates 5-HT7 receptor modulation of AMPA receptor 
neurotransmission (Zamanillo et al., 1999). In support of this, 5-HT7 receptors enhance 
AMPA receptor-mediated transmission in the hippocampus via an action on post-synaptic 
neurones (Costa et al., 2012).  
In the present study we have investigated the ability of the 5-HT7 receptor to impact 
glutamatergic neurotransmission in the hippocampus and have demonstrated that the receptor 
promotes protein kinase A (PKA) -mediated phosphorylation of native GluA1 AMPA 
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receptor subunits (Alexander et al., 2013) in rat hippocampus, which results in an increase in 
phosphorylated (S845) GluA1 AMPA receptor subunit insertion into the neuronal membrane; 
this likely contributes to the evident increase in AMPA receptor-mediated neurotransmission 
in the hippocampus both in vitro and in vivo.  
 
Materials and methods 
Materials 
5-HT and papaverine were purchased from Sigma-Aldrich, St. Louis, MO, USA; SB258719, 
GR113808, SB399885, AS-19, Rolipram, H89 were from Tocris Bioscience, Ellisville, MO, 
USA. Laboratory reagents were from Sigma-Adrich unless otherwise specified. Cell culture 
reagents were purchased from Gibco/Invitrogen (Life Technologies, Paisley, UK) except 
where otherwise indicated.   
 
Use of animals 
All animal protocols were in accordance with the European Communities Council Directive 
2010/63/EU and Italian or UK legislation acts concerning animal experimentation. The 
experimental protocol was approved by the Local Ethics Committees. Efforts were made to 
minimise animal suffering and to reduce the number of animals used. All in vivo experiments 
were performed in accordance with ARRIVE guidelines. (Kilkenny et al., 2010; McGrath et 
al., 2010). 
 
Preparation of rat neurone or astrocyte cultures  
Hippocampal predominantly neuronal cultures were obtained from embryos at day 18/19 of 
gestation (E18/19) of Sprague-Dawley rats (embryos killed by decapitation). Hippocampi 
were quickly isolated into Hank's Balanced Salt Solution (HBSS; pH 7.3 buffer containing 
Hepes (10 mM), penicillin (100 U/ml) and streptomycin (100 µg/ml) 4°C) before incubation 
of trypsin (0.1%; 37°C, 10 min (for the last 5 min of this incubation, DNAse I (166 µg/ml) 
was added)), washed with HBSS buffer containing 10% foetal bovine serum (FBS) and cells 
dissociated by triturating. Cells were placed in Poly-L-lysine (MW >30000 kDa) coated 
plates (density of 700-800 cells/mm
2
) in serum-free NEUROBASAL™ Medium 
supplemented with B-27
®
 Supplement, glutamine (500 µM), glutamate (12.5 µM), penicillin 
(100 U/ml) and streptomycin (100 µg/ml). Cells were grown at 37°C, 5% CO2 and half the 
volume of the medium was replaced after 4 days with complete medium minus glutamate. 
For all assays, primary cells were used between 8-10 days in culture.  
 
Phenotype and purity of cell cultures 
Purity of cultured cells was assessed by phenotyping with primary antibodies (rabbit anti-
GFAP; 1:1000 (Sigma-Aldrich) or anti-NeuN (mouse 1:200 (Chemicon, Merck Millipore)). 
with 5 fields per coverslip acquired using a LEICA microscope (IM 50 program; 20 x 
objective) with positive cells counted manually.     
  
This article is protected by copyright. All rights reserved. 
 
RNA extraction and quantification 
Total RNA from cultured cells was extracted using RNeasy mini kit from Qiagen (Qiagen 
Inc) following the manufacturer’s instructions. Genomic DNA was removed using RNAse-
free DNase I (Applied Biosystems, Life Technologies). Purified RNA was quantified using 
an Agilent 2100 Bioanalyzer following the Agilent RNA 6000 Nano kit protocol (Agilent 
Technologies Inc).  
 
Reverse Transcribed PCR 
cDNA was generated by reverse transcription of total RNA (100 ng) using TaqMan Reverse 
Transcription Reagents (Applied Biosystems, Life Technologies); 1x RT buffer, MgCl2 (2.5 
mM), dNTPs (1 mM), random hexamers (2.5 µM), RNase Inhibitor (0.4 U/µl), MultiScribe 
RT (1.25 U/µl). The mixture was incubated consecutively at 25°C (10 min), 48°C (30 min) 
and 95°C (5 min). PCR was performed using HotStarTaq(R) PCR from Qiagen: 10 ng 
cDNA, 1x PCR buffer, 200 µM dNTPs, 300 nM Primers, 1 unit Taq in DNase-free water. 
After 15 min incubation (95°C), 40 cycles of amplification were performed (30 sec 
denaturation at 95°C, 30 sec annealing at 60°C, and 40 sec extension at 72°C) before 
termination with 10 min extension at 72°C. Primer pairs were as follows:  
 
5-HT7 receptor:  
Forward; ATCTTCGGCCACTTCTTCTGCAACG  
Reverse; CAGCACAAACTCGGATCTCTCGGG  
 
5-HT6 receptor: 
Forward; CCATCTGCTTCACCTACTGC  
Reverse; TCTGAATCTGAGTTTGGCGG  
 
5-HT4 receptor:  
Forward; TTGGCTGCTTTGGTCTCTGTCCGC;  
Reverse; TGCAAGGCTGGAACAACATCGGC.  
 
PCR products were separated electrophoretically (1.5% agarose gels in 1x TAE buffer (Tris 
40 mM, glacial acetic acid 1 mM, 0.1% EDTA, pH 8)) with SYBR safe DNA gel stain 
(Invitrogen, Life Technologies) running alongside DNA molecular weight markers (100 bp 
ladder, Invitrogen, Life Technologies) for 1 hour at 100 V. 
 
Assessment of cAMP concentration 
cAMP was quantified using the cAMP Hi Range kit (Cisbio) according to the manufacturer’s 
instructions.  
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Sample preparation and measurement of total CREB, pCREB, and phospho-p38 MAPK 
Cells were removed by scraping in lysis buffer (Tris (10 mM; pH 7.4), NaCl (100 mM), 
EDTA (1 mM), EGTA (1 mM), NaF (1 mM), Na4P2O7 (20 mM), Na3VO4 (2 mM), 1% Triton 
X-100, 10% glycerol, 0.1% sodium dodecyl sulfate (SDS), 0.5% deoxycholate, 
phenylmethanesulfonyl fluoride (2 mM), protease inhibitors (Complete Mini, Roche Life 
Science, Sigma-Aldrich) and 1% phosphatase inhibitors I and II (Sigma-Aldrich)). Cells 
lysates were incubated at 4 °C for 30 min before centrifugation (10 min at 13000 x g) and the 
supernatants quantified for total CREB and Serine
133-
phosphorylated CREB by ELISA 
(Invitrogen, Life Technologies) accodrding to the manufacturer’s instructions. Phospho-p38 
MAP Kinase levels were also measured by ELISA (Cell Signaling Technology) following the 
manufacturer’s instructions. 
 
Isolation of cell surface proteins  
Cell surface proteins were isolated using EZ-link sulfo-NHS-SS-Biotin (Pierce) at 4°C. Cells 
were incubated with biotin (1 mg/ml; 20 min) dissolved in PBS. After three rinses in ice-cold 
glycine (50 mM) in PBS, cells were scraped into homogenization buffer (0.1% SDS, 0.5% 
NP40, 0.5% sodium deoxycholate, 150 mM NaCl, Complete mini protease inhibitors, 
phosphatase inhibitors cocktail I and II in PBS, pH 7.4), centrifuged (10,000 x g, 20 min) and 
the supernatant represented the total protein extract. For purification of the biotinylated 
surface protein fraction, 50 µg of total proteins were incubated with 80 µl of 50% slurry 
Neutravidin resin (Pierce) for 2 h at 4ºC. After washing, biotinylated proteins were eluted 
(100 µl of elution buffer; Invitrogen NuPage LDS sample buffer with ditiothreitol (50 mM)), 
heated at 95ºC for 5 min before centrifugation (1,000 x g for 2 min).  
Protein concentration was determined using Bio-Rad reagents (Bio-Rad Laboratories Inc., 
Hercules, CA, USA) based on the Bradford assay. When protein concentration was expected 
to be low, the micro BCA kit was adopted (Pierce). 
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)-Western 
blotting 
Proteins were separated using SDS-PAGE in an XCell SureLock™ Mini-Cell (Invitrogen, 
Life Technologies). Equal amounts of cell lysates (~6-10 µg protein) in 4 x NuPAGE® LDS 
Sample Buffer and 10 x NuPAGE® Sample Reducing Agent were boiled for 5 min, 
centrifuged briefly and loaded in pre-cast gels (1.5 mm 4-12% Novex Bis-Tris Pre-Cast Mini 
Gels, Invitrogen, Life Technologies). Prestained protein molecular weight markers (Novex® 
Sharp Pre-stained Protein Standard) were loaded in parallel. Electrophoresis was performed 
(50V for 1 h) and proteins transferred to polyvinylidene difluoride (PVDF) membranes 
(Amersham) using a Mini Trans-Blot module (Bio-Rad) in Transfer Buffer (25 mM Tris, 192 
mM Glycine, 20% methanol, pH 8.3) at 40-50V for 2 h. PVDF membranes were blocked (5% 
skimmed dried milk in Tris Buffered Saline (TBS: 50 mM Tris HCl, 280 mM NaCl, 2.7 mM 
KCl, pH 7.6; 1 hr) containing 0.1% Tween-20) and then incubated with the relevant primary 
antibodies; either rabbit anti-GluA1 Ser845P (Sigma-Aldrich; 1:1000), rabbit anti-GluA1 
(Millipore; 1:1000), rabbit anti-pan Cadherine (Abcam; 1:1000) or mouse anti-GAPDH 
(Santa Cruz Biotechnology; 1:10000). Membranes were washed (3 x 10 min) with 0.1% 
Tween-20 in TBS before incubation (1 h at room temperature) with peroxidase-conjugated 
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secondary antibodies (goat anti-rabbit IgG-HRP or goat anti-mouse IgG-HRP, Santa Cruz; 
1:5000). The chemiluminescence reaction was developed with ECL Plus (Amersham) and 
detected with Luminescent Image Analyzer LAS-4000mini (Fujifilm). Optical densities were 
determined by densitometric analysis with Quantity One software (Bio-Rad).  
 
Electrophysiologyical recording in the hippocampus in vivo 
Adult male Sprague-Dawley rats (250-350 g, n=12) were initially anaesthetized with 
isoflurane and subsequently with chloral hydrate (400 mg/kg i.p.) with anaesthetic depth 
maintained by constant intravenous infusion (80-120 mg/kg/hr) adjusted dependent on 
corneal reflex, withdrawal response to paw-pinch and the stability of monitored 
cardiovascular variables. Core body temperature was maintained at 37 ± 1°C. The right 
femoral vein, artery and the trachea were cannulated to permit, respectively: administration of 
supplemental anaesthetic; the recording of arterial blood pressure via a pressure transducer 
and amplifier (Neurolog module NL108, Digitimer), and the maintenance of a clear airway. 
Animals were placed in a stereotaxic frame (Narishige ST-7) and the dorsal brain surface 
overlying the hippocampus exposed by craniotomy. A small incision was made in the dura 
and a multi-barrel recording electrode (Kation Scientific) was lowered vertically through the 
cortex to the CA3 pyramidal layer of the hippocampus according to the following stereotaxic 
boundaries (Paxinos & Watson, 1998): Bregma -3.9 – 4.4 mm, lateral 3.7 – 4.2 mm, depth 
3.6 – 4.2 mm below pial surface. Unitary activity was recorded through an extracellular 
carbon fibre microelectrode and, using the Neurolog system, the signal was amplified (x10 k, 
module NL104) and filtered (bandwidth 1 – 30 kHz, module NL125), with the conditioned 
output being captured on a PC using a micro1401 interface with Spike 2 software (CED). 
Multi-barrel electrodes were filled with 5-CT (DP-5-CT, 1-10 mM), WAY-100,635 (1-10 
mM), AMPA (5 mM in 195 mM NaCl; pH 8) and NBQX (disodium salt, 1 mM in ddH2O; 
pH 8) and for current balancing and recording site marking, Chicago Sky Blue. Initially, 
baseline CA3 pyramidal neurone activity was examined during iontophoretic administration 
of 5-CT alone and in the presence of the 5-HT1A receptor antagonist WAY-100,635. 
Subsequent experiments examined the response to 5-CT, with and without concomitant 
application of WAY-100,635, on neuronal bursts of firing induced by cyclical (5/30 s) 
iontophoretic administration of AMPA. NBQX was iontophoretically administered at the end 
of experiments to confirm that AMPA-induced excitations were selective. Stable baseline or 
AMPA-evoked neuronal activity was recorded for a minimum of 5 minutes before test 
substance examination. Neurones with unstable activity or whose recording location lay 
outside the pyramidal layer were excluded from analyses. Neuronal activity was measured in 
spikes per second (Hz) for a minimum period of 60 s before and during test compound 
treatment. 
Subsequent to electrophysiological recordings in vivo, rats were killed without recovery of 
consciousness by an overdose of sodium pentobarbitone (200 mg/kg), followed by cervical 
dislocation. 
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Electrophysiologyical recording in the hippocampus in vitro 
Male Sprague Dawley rats (6-8 weeks old) were killed by anaesthetic overdose using 
isoflurane inhalation. Transverse hippocampal slices (400 µm thickness) were cut using a 
vibratome (Leica VTS1000) in chilled (<4°C) carbogenated (95% O2 / 5% CO2) artificial 
cerebrospinal fluid (aCSF; NaCl, 127 mM; KCl, 1.9 mM; KH2PO4, 1.2 mM; CaCl2, 2.4 mM; 
MgCl2, 1.3 mM; NaHCO3, 26 mM; D-glucose, 10 mM).  Slices were maintained in aCSF at 
room
 
temperature for a minimum of 1 hr before transferring to a custom-built recording 
chamber to commence whole-cell recordings from hippocampal CA3 pyramidal neurones 
with an Axopatch 1D amplifier (Molecular Devices LLC), using the blind version of the 
patch-clamp technique (see Pickering et al., 1991). Patch pipettes were pulled from thin-
walled borosilicate glass (GC150-TF10, Harvard Apparatus) with resistances between 3 and 
8 MΩ when filled with intracellular solution of the following composition: Kgluconate, 130 
mM; KCl, 10 mM; EGTA-Na, 1 mM; HEPES, 10 mM; Na2ATP, 4 mM; Na2GTP, 0.3 mM 
and Lucifer yellow, 2 mM; pH-adjusted to 7.4 with KOH, osmolarity-adjusted to 310 mOsm 
with sucrose. Data was filtered at 2-5 kHz (current-clamp) or 1 kHz (voltage-clamp), 
digitised at 10 kHz (Digidata 1322, Molecular Devices LLC) and recorded on a PC running 
Clampex 9.1 software (Molecular Devices LLC). After achieving whole-cell access 
current/voltage relations were generated to identify intrinsic membrane conductances 
consistent with CA3 pyramidal neurones. In voltage-clamp experiments, mossy fibre pathway 
synaptic inputs were stimulated using a concentric bipolar stainless steel electrode and 
AMPA receptor-mediated excitatory postsynaptic currents (EPSCs) pharmacologically 
isolated using D-AP5 (25 μM), bicuculline (10 μM) and CGP-55845 (200 nM) to block 
NMDA, GABAA and GABAB receptor-mediated synaptic inputs, respectively. Where 
relevant, 5-HT1A receptors were also blocked with WAY-100,635 (1 μM) prior to obtaining a 
stable baseline of at least 5 minutes and then examining the effect of 5-CT (10 μM) 
application, before a final period of wash and confirmation of AMPA-mediated responses 
with NBQX (10 μM). In current-clamp experiments, a minimum of two stable responses were 
obtained to AMPA application (10 – 20 μM, 2-6 s) in the presence of WAY-100,635 (1 μM) 
and tetrodotoxin (TTX, 1 μM), before repeating in the presence of 5-CT (10 μM), a period of 
wash and, where possible, perfusion of SB258719 (20 μM) and a further 5-CT response 
examination. After completion of experiments, slices were fixed in 4% paraformaldehyde for 
a minimum of 48 hrs, before clearing with DMSO (>4 hrs), and visualisation of recorded 
cells using fluorescence microscopy to confirm their location within the CA3 pyramidal layer 
and characteristic morphology.  
 
Data Analysis 
Drug concentration-response curves were fitted to a four parameter logistic equation using 
GraphPad Prism 5 (GraphPad Software Inc). Agonist potency was expressed as pEC50 (-log 
EC50). The inhibition of antagonists was expressed as the pIC50 (–logIC50), where IC50 
represents the concentration of drug inhibiting 50% of agonist maximal response. pKB values 
for antagonists were determined using the equation: pKB =(-log([antagonist]/(concentration 
ratio-1)) where concentration ratio = ratio of the agonist EC50 in the presence and in the 
absence of the antagonist. Where variance is indicated, data represent mean±SEM. 
For biochemical assays, where occurring, normalisation was a % change from the control 
group's individual value for a given experiment with individual values then used to generate 
mean±SEM. Statistical analysis was only performed if the n value was 5 or greater. Where 
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more than two groups were compared, a Kruskal-Wallis ANOVA was performed. If P<0.05 
from the Kruskal-Wallis ANOVA, or where just two groups were to be compared, a Mann-
Whitney U test was performed with P<0.05 considered a statistically significant difference 
between groups.  
Analysis of electrophysiological data was carried out using Clampfit 9.1 software (Molecular 
Devices LLC). For voltage-clamp data, the mean maximum electrically-evoked EPSC 
amplitude measured from a minimum of 5 consecutive sweeps (60 s) was compared with a 
temporally-matched period during the peak response to 5-CT. For current-clamp data, the 
area under the curve (in V.ms
-1
) of AMPA-evoked responses was the primary measurement, 
the baseline was taken as the response immediately preceding 5-CT perfusion. All data are 
represented as mean±SEM. Comparisons between treatment periods were made using the 
paired student’s t-test. Probability (P) values < 0.05 were considered significant. 
 
Results 
5-HT7 receptor mRNA expression in primary culture of hippocampal cells 
The purity of primary cell cultures after 8-10 days in vitro was evaluated by 
immunocytochemistry for the neuronal marker NeuN and the astrocyte marker glial fibrillary 
acidic protein (GFAP); the percentage of hippocampal NeuN- and GFAP-positive cells vs. 
DAPI-stained cells was around 80% and 10%, respectively (Supplementary Figure S1). At 
the same end-point of 8-10 days in vitro, expression of 5-HT7 receptor mRNA was evident by 
RT-PCR with appropriate sized product detected from cultured hippocampal cells (and also 
cultured cerebral cortex cells and adult hippocampus; Figure 1). Hereafter the hippocampal 
primary cells enriched considerably for neurones using appropriate culture conditions will be 
termed hippocampal neurones. 
 
Ability of 5-HT to increase intracellular cAMP levels in hippocampal neurones and 
pharmacological definition of the receptor 
5-HT displayed a concentration-dependent ability to increase cAMP levels in hippocampal 
neurones (pEC50 of 7.2±0.2; Hill slope of 1.2±0.2; Figure 2A). Neither the selective 5-HT4 
receptor antagonist, GR113808, nor the selective 5-HT6 receptor antagonist, SB399885 
(either at concentrations up to 1.0 µM) prevented the ability of a sub-maximal concentration 
of 5-HT (100 nM) to increase cAMP levels (the increase in cAMP levels evident at the 
relatively high micromolar concentrations of SB399885 may be a consequence of 
engagement with additional receptors; Hirst et al, 2006). In contrast, the selective 5-HT7 
receptor antagonist, SB258719, prevented the ability of 5-HT (100 nM) to increase cAMP 
levels in a concentration dependent manner (pIC50 of 7.95±0.09, n=3; Figure 2B). 
Furthermore, SB258719 displayed competitive antagonism of the 5-HT-evoked response 
(pKb of 8.23±0.1; Figure 2C).   
 
Influence of 5-HT7 receptors upon pCREB levels in hippocampal neurones 
5-HT (1.0 µM) induced an increase in relative pCREB levels (pCREB:CREB ratio) above 
basal levels although the signal was transient (evident at 5 min of incubation with 5-HT but 
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not at 10 minutes and longer; Figure 3A). Prior incubation with SB258719 (100 nM – 10 µM) 
inhibited the ability of 5-HT (5 min) to increase relative pCREB levels in a concentration-
dependent manner (Figure 3B).  
 
5-HT (1.0 µM) failed to modify phosphorylated p38 MAP kinase levels in the hippocampal 
neurones (Supplementary Figure S2). This contrasted the ability of 5-HT (1.0 µM) to increase 
phosphorylated p38 MAP kinase levels in rat primary astrocytes (Supplementary Figure S2), 
the latter being consistent with previous studies (e.g. Lieb et al., 2005). 
 
Influence of 5-HT7 receptors upon GluA1 expression and post-translational modification 
in hippocampal neurones 
In hippocampal neurones, either 5-HT (1.0 µM; 5 min) or FSK (10 µM; 5 min) increased the 
relative total GluA1 protein level and to a greater extent the relative protein level of pGluA1 
(Ser845) (Supplementary Figure 3; Figure 4).  
The prior application of either GR113808 (up to10 µM) or SB399885 (up to 10 µM) failed to 
prevent the impact of 5-HT upon relative total GluA1 or pGluA1 (Ser845) protein levels, 
whereas SB258719 (10 µM) reduced the ability of 5-HT to increase relative pGluA1 (Ser845) 
protein levels (Figure 4) although not total GluA1 protein levels (Figure 4B).  
 
Similar to 5-HT, the selective 5-HT7 receptor agonist AS-19 (1.0 µM) increased relative 
pGluA1(Ser845) levels and the action of AS-19 was prevented completely by prior 
application of SB258719 (10 µM; Figure 4). However, AS-19 (1.0 µM) did not increase total 
GluA1 protein levels (Figure 4C). This lack of activity associated with AS-19, and the failure 
of SB258719 (10 µM) to prevent the 5-HT-induced increase in total GluA1 protein levels 
suggests the latter effect was not mediated via the 5-HT7 receptor.  
 
Influence of 5-HT7 receptors upon cell surface GluA1 AMPA receptor expression in 
hippocampal neurones 
Treatment of hippocampal neurones with 5-HT (1.0 µM) increased cell surface membrane 
expression of pGluA1(Ser845) for the three time points investigated (5, 10 and 30 min; 
Figure 5). In contrast, no difference in cell surface levels of GluA1 was detected (Figure 5). 
The ability of 5-HT (1.0 µM) to increase cell surface membrane expression of 
pGluA1(Ser845) was prevented by prior application of either SB258719 (10 µM; Figure 6) or 
the protein kinase A inhibitor, H89 (10 µM; Figure 6). As demonstrated in other experiments, 
SB258719 (10 µM) also inhibited the 5-HT-induced increase in pGluA1(Ser845) in total cell 
extracts, as did H89 (10 µM; Figure 6).  
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Ability of PDE4 and PDE10 to regulate 5-HT-induced pGluA1(Ser845) in hippocampal 
neurones 
In hippocampal neurones, either the phosphodiesterase (PDE4) inhibitor, rolipram (10 µM) or 
the PDE10 inhibitor, papaverine (10 µM) increased pGluA1(Ser845) levels (Supplementary 
Figure 4), which were further increased by combination with 5-HT (1.0 µM) to levels above 
those detected with 5-HT (1.0 µM) alone (Supplementary Figure 4). In contrast, neither 
rolipram nor papaverine impacted significantly total GluA1 when applied alone or in 
combination with 5-HT (Supplementary Figure 4).  
 
Ability of the 5-HT1A/7 receptor agonist 5-CT to alter the firing pattern of hippocampal CA3 
neurones in vivo 
Extracellular recordings were performed in anaesthetized rats (n=12) examining the effects of 
iontophoretic administration of the 5-HT1A/7 receptor agonist, 5-CT (for electrode placement 
see Supplementary Figure 5). In all, recordings were made from 16 hippocampal CA3 
pyramidal neurones, of which 50% (8/16) were active (firing rate of 7.9±3.0 Hz), whilst the 
remaining were quiescent.  In 7 of these active neurones, 5-CT administration was tested on 
baseline activity, with neuronal activity significantly reduced from 15.1±2.8 to 9.7±3.7 Hz in 
4 of these 7 neurones, and activity increasing from 0.8±0.4 to 4.9±1.7 Hz in the remaining 3 
neurones (Figure 7A and 7C). To remove the potentially confounding effect of 5-HT1A 
receptor activation by 5-CT, the selective 5-HT1A receptor antagonist, WAY-100,635, was 
applied to 7 neurones, which revealed an almost exclusively excitatory response to 5-CT; the 
firing rate of 6 of these 7 neurones increasing significantly from a mean of 6.2±2.2 to 
11.5±2.5 Hz (P<0.05, n=6, Figure 7A and 7D). In only a single neurone (1/7) was activity 
reduced (from 12.7 to 6.2 Hz; Figure 7A).  
The impact of 5-CT administration was also examined on bursts of action potential firing of 
hippocampal CA3 pyramidal neurones induced by cyclical administration of AMPA. When 
tested with 5-CT alone, AMPA-evoked firing was significantly reduced in the majority (6/7) 
of neurones (from 29.0±12.0 to 13.6±6.2 Hz; Figure 7B) and in the remaining neurone firing 
increased from 6.3 to 7.9 Hz (Figure 7B). However, in the presence of the selective 5-HT1A 
receptor antagonist WAY-100,635, a predominant excitatory action of 5-CT was revealed, 
with AMPA-induced neuronal firing increased significantly in 5 of 7 neurones (from 
28.6±8.7 to 50.1±13.8 Hz; Figure 7B and 7E) with the activity of the remaining 2 neurones 
being reduced from 13.2 to 3.9 Hz (Figure 7B).  
 
Ability of the 5-HT7 receptor to modify synaptic input into hippocampal CA3 pyramidal 
neurones in vitro 
To determine whether 5-HT7 receptor activation could modify the magnitude of AMPA 
receptor-mediated synaptic input to CA3 pyramidal neurones, whole-cell patch-clamp 
recordings were performed from rat hippocampal slices, electrically stimulating mossy fibre 
inputs to evoke EPSCs (for electrode placement see Supplementary Figure S5). In the 
presence of the 5-HT1A receptor antagonist, WAY100,635 (1.0 µM), the 5-HT1A/7 receptor 
agonist, 5-CT (10 µM) revealed a mixed response with EPSC amplitude reduced to 
62.4±1.6% of control levels in 3 of 9 neurones (from 77.2±23.0 to 48.8±15.6 pA; Figure 8A, 
8C top and 8D), and enhanced to 150.8±14.5% of control levels in 6 of 9 neurones (from 
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69.6±15.2 to 101.9±20.5 pA; P<0.05, n=6, Figure 8B, 8C bottom and 8D). Both these 
responses partially recovered to pre-5-CT application levels upon washout of 5-CT (to 
72.4±24.3 and 86.2±17.5 pA, respectively). EPSCs were confirmed as AMPA receptor-
mediated via administration of the selective AMPA receptor antagonist, NBQX (10 μM) 
which abolished EPSC amplitude (Figure 8A, 8B, 8C and 8D). 
Further patch-clamp experiments were performed to determine the effects of 5-HT7 receptor 
activation upon isolated postsynaptic AMPA receptor-mediated activity by examining the 
effects of 5-CT (10 µM) administration, in the presence of tetrodotoxin (1.0 µM) and WAY-
100,635 (1.0 µM), upon short periods of depolarisation induced by brief perfusion with 
AMPA (20 µM). These current-clamp experiments revealed an almost exclusive 
augmentation of AMPA-induced depolarisation by 5-CT (10 µM), with the AUC of 8 
neurones enhanced significantly from 1169±167 to 1827±284 V.ms
-1
 (156.8±10.4% of 
control; P<0.01, n=8, Figure 9A, 9B and 9D), with recovery following washout of 5-CT (to 
1262±236 V.ms
-1
, 104.7±10.0% of pre-5-CT application; Figure 9D). In 3 neurones, AUC 
analysis revealed a similar mean control 5-CT increase to 157.2 ± 4.7% of AMPA-responses 
(n=3), which was reduced to 111.0±14.7%, when repeated in the added presence of the 5-HT7 
receptor antagonist SB258719 (1.0 µM; Figure 9C and 9D). 
 
Discussion 
The present studies originated to better understand the mechanisms that might underlie the 
ability of the 5-HT7 receptor to modulate glutamate-mediated neurotransmission (Bacon and 
Beck, 2000; Bickmeyer et al., 2002; Gill et al., 2002; Tokarski et al., 2003; 2005; Costa et al., 
2012), which may have relevance to the ability of the 5-HT7 receptor to modulate memory 
and learning (Meneses, 2004; Perez-Garcia and Meneses, 2005; Ballaz et al., 2007; Eriksson 
et al., 2008; Sarkisyan and Hedlund, 2009; Horisawa et al., 2011; Waters et al., 2012; Freret 
et al., 2014) and relevant physiological phenomena such as LTP. 
Initially our investigations used primary cultures of rat hippocampus under suitable 
conditions to favour the culture of neurones. The cultured hippocampal neurones expressed 
5-HT7 receptor transcripts and pharmacological studies demonstrated that the 5-HT7 receptor 
increased cAMP levels as well as the phosphorylation of the downstream signalling 
transcription factor, CREB (cAMP response element-binding protein). A key finding in the 
present study was that 5-HT7 receptor activation signalled via the cAMP-dependent kinase, 
protein kinase A (PKA), via phosphorylation of serine 845 within the C-terminal tail of the 
GluA1 AMPA receptor subunit. This post-transcriptional modification promoted expression 
of the phosphorylated GluA1-S845 subunit in the neuronal surface membrane.  
Glutamate AMPA receptors are the primary means of relaying excitatory synaptic 
neurotransmission and regulation of their function impacts synaptic plasticity and associated 
memory function. It is well established that phosphorylation of AMPA receptor subunits 
modifies their activity (e.g. Song and Huganir, 2002); the GluA1 subunit forms homomeric 
receptors and also contributes a major component of the predominant heteromeric AMPA 
receptor (GluA1/2) in the hippocampus (Lu et al., 2009). The GluA1 AMPA receptor subunit 
possesses two phosphorylation sites (serine 831 and 845; S831 and S845); S831 is a substrate 
for calcium/calmodulin-dependent protein kinase (CaMKII) and protein kinase C (Roche et 
al., 1996; Barria et al., 1997; Mammen et al., 1997) whereas S845 is a substrate for PKA 
(Roche et al., 1996). Relevant to the present study, phosphorylation of S845 within GluA1 
subunits by directly enhancing cAMP levels (via either direct stimulation of adenylate 
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cyclase by forskolin or inhibition of phosphodiesterase [PDE] by rolipram) promotes cell 
surface expression of the phosphorylated S845 GluA1 subunit (Esterban et al., 2003; Oh et al., 
2006) and promotes AMPA receptor function (Roche et al., 1996; Lee et al., 2000; Oh et al., 
2006; He et al., 2009; Makino and Malinow, 2009). In the present studies activation of the 5-
HT7 receptor increased cell surface expression of phosphorylated S845 GluA1 via a PKA-
dependent mechanism, consistent with the 5-HT7 receptor elevating cAMP levels. The 
involvement of the 5-HT7 receptor was indicated by a number of lines of evidence. Thus, 5-
HT7 receptor transcripts were expressed by the primary neurones in culture and their 
functional involvement verified pharmacologically by the comparable action to 5-HT (pEC50 
= 7.2) of the selective 5-HT7 receptor agonist AS-19 at a just-maximal concentration to 
activate the 5-HT7 receptor (1.0 µM; Brenchat et al., 2009); the apparent lower efficacy of 
AS-19 compared to 5-HT may reflect the partial agonist action of AS-19 demonstrated in 
other assays in vitro (Brenchat et al., 2009). Furthermore, the relatively selective 5-HT7 
receptor antagonist, SB258719 (Thomas et al., 1998; 1999) antagonised the 5-HT-evoked 
responses; SB258719 also displayed competitive receptor antagonism of the 5-HT-induced 
increase in cAMP levels within the primary hippocampal cultures generating a pKb of 8.23, 
consistent with the affinity of SB258719 for the 5-HT7 receptor (Thomas et al., 1998; 1999). 
Furthermore, two additional 5-HT receptor subtypes known to increase cAMP production, 
the 5-HT4 and 5-HT6 receptors, did not appear relevant to the responses detected in the 
present studies since the selective 5-HT4 and 5-HT6 receptor antagonists, GR113808 (Gale et 
al., 1994) and SB399885 (Hirst et al., 2006), failed to inhibit 5-HT-induced elevated cAMP 
levels in the hippocampal primary cell cultures at pharmacologically relevent concentrations 
(upto 1 µM). Involvement of cAMP was also indicated by the effect of phosphodiesterase 
inhibition; thus 5-HT7 receptor-mediated phosphorylation of GluA1 was increased by the 
non-selective PDE4 and PDE10 inhibitors, rolipram and papaverine, respectively, with both 
PDE4 and PDE10 known to be expressed in hippocampus (Menniti et al., 2006).   
Consistent with the biochemical studies demonstrating the 5-HT7 receptor promoted 
expression of phosphorylated GluA1-S845 subunit in the neuronal membrane of cells derived 
from all fields of the hippocampus, electrophysiological recordings in the CA3 field of the 
hippocampus in vivo revealed 5-HT7 receptor activation increased spontaneous activity and 
enhanced AMPA-induced increases in action potential firing. Furthermore, 
electrophysiolgical recordings in vitro demonstrated that whilst selective AMPA receptor-
mediated synaptic transmission via mossy-fibre inputs to CA3 pyramidal neurones could be 
enhanced or depressed in the presence of 5-CT, AMPA-induced whole-cell postsynaptic 
currents were consistently increased by 5-HT7 receptor activation.       
The present studies confirmed the role of 5-HT7 receptors in the regulation of CREB 
phosphorylation in hippocampal neurones (Mahgoub et al., 2006). In contrast, no effect was 
apparent by 5-HT upon p38 MAP kinase in the same preparation, despite studies run in 
parallel that demonstrated an effect of 5-HT to increase p38 MAP kinase phosphorylation in 
rat cortical astrocytes in culture, which also expressed 5-HT7 receptor mRNA (data not 
shown). The latter is consistent with previous studies (Lieb et al., 2005; Mahe et al., 2005) 
and hence our data suggests differential cell signaling for the 5-HT7 receptor in neurones 
compared to astrocytes. 
 
As well as the relatively short-term actions of 5-HT7 receptors investigated in the present 
studies, relevant longer term actions mediated via the 5-HT7 receptor are also evident 
including elevation in glutamate levels in vivo indicating enhanced excitatory synaptic tone 
(Canese et al., 2015) and plastic neuronal remodelling (Kvachnina et al., 2005; Kobe et al., 
2012; Speranza et al., 2013; Canese et al., 2015), which may underlie structural changes 
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associated with memory formation. 
 
Interestingly, a previous report suggests the 5-HT1B receptor evokes CaMKII mediated 
phosphorylation of the GluA1 subunit at a further phosphorylation site in the C-terminus, 
S831, which also contributes to 5-HT-induced potentiation of neurotransmission via a post-
synaptic mechanism (Cai et al., 2013). 
In summary, the present study has demonstrated that 5-HT7 receptor activation in rat 
hippocampal neurones signals a protein kinase A-dependent phosphorylation of serine 845 
within the GluA1 AMPA receptor subunit that results in increased levels of phosphorylated 
S845 GluA1 subunits within the neuronal membrane that likely manifests the evident 
enhanced AMPA receptor mediated neurotransmission within the rat hippocampus in vitro 
and in vivo. 
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Figure 1. Expression of the 5-HT7 receptor by hippocampal primary cells in culture in 
comparison to expression by primary cerebral cortex cells and adult rat hippocampal tissue. 
Representative RT-PCR of cDNA products of around 850 bp from adult rat hippocampi 
(Adult; lanes 5 and 6) and primary cells cultured from the hippocampi (Hipp; lanes 3 and 4) 
and cerebral cortices (Cx; lanes 1 and 2) of E18/19 rat embryos. Lanes 2, 4 and 6 show lack 
of product when the enzyme was omitted from the RT step. Each line of the ladder (M) 
represents a band size increase of 100 bp. Similar results were obtained from three 
independent experiments.   
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Figure 2. Ability of the 5-HT7 receptor to increase cAMP levels in hippocampal neurones. A: 
Concentration-dependent ability of 5-HT to increase intracellular cAMP levels. B: 
Concentration-dependent ability of the selective 5-HT7 receptor antagonist, SB258719, to 
inhibit the 5-HT (100 nM) induced increase in cAMP levels and lack of inhibition by the 
selective 5-HT4 and 5-HT6 receptor antagonists (GR113808 and SB399885, respectively). 
Data represent the percentage of cAMP increase after 5-HT addition vs. basal levels (mean ± 
SEM, n=3). C: Concentration-dependent ability of 5-HT to increase intracellular cAMP 
levels in the absence and presence of the selective 5-HT7 receptor antagonist, SB258719 (100 
nM); the rightward shift in the 5-HT concentration-response curve is indicative of 
competitive antagonism by SB258719. Data represent mean ± SEM, n=3.     
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Figure 3. Ability of the 5-HT7 receptor to increase CREB phosphorylation in hippocampal 
neurones. A: Time-dependent effect of 5-HT (1.0 µM) upon CREB phosphorylation 
(forskolin [10 µM] applied for 30 min). Data were the mean±SEM of eight (5-HT [5 min]) or 
three (5-HT [10-60 min] or forskolin [FSK]) independent experiments and represent the 
pCREB/total CREB ratio of treated cells vs. basal levels (*P<0.05, **P<0.01  5-HT [5 min] 
vs. basal levels; Mann-Whitney U test). B: Concentration-dependent ability of the selective 5-
HT7 receptor antagonist, SB258719, to inhibit 5-HT (1.0 µM; 5 min) induced CREB 
phosphorylation. Data represent the mean±SEM from three independent experiments. 
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Figure 4. 5-HT7 receptor activation increases phosphorylation of GluA1 at serine
845
 in 
hippocampal neurones A: Representative immunoblots of hippocampal neurones treated for 
15 min with vehicle (DMSO 0.1%), GR113808 (1.0 µM; 5-HT4 receptor antagonist) 
SB399885 (1.0 µM; 5-HT6 receptor antagonist), or SB258719 (10 µM; 5-HT7 receptor 
antagonist) followed by treatment with 5-HT (1.0 µM; left hand panel) or AS19 (1.0 µM; 
right hand panel) for 5 min. B-C: Quantification of pGluA1 (Ser845) and total GluA1. Ratio 
of pGluA1 (Ser845)/GAPDH (glyceraldehyde 3-phosphate dehydrogenase), total 
GluA1/GAPDH and pGluA1 (Ser845)/total GluA1 are expressed as fold increase ± SEM 
with respect to basal levels from seven (5-HT), six (5-HT plus SB258719), four (AS-19) or 
three independent experiments (P<0.01 Kruskal-Wallis ANOVA; *P<0.05 versus basal 
Mann-Whitney U test). 
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Figure 5. Ability of 5-HT to affect cell surface membrane expression of pGluA1 (Ser845). A: 
Representative immunoblots of neurones treated with 5-HT (1.0 µM) for 5-30 mins. B-C: 
Quantification of pGluA1 (Ser845) and total GluA1 in the total cell extract (left) and in the 
surface fraction (right). Amount of proteins were normalised using GAPDH and pan-
cadherine in the total cell extract and in the cell surface fraction, respectively. Value are 
expressed as fold increase ± SEM with respect to basal levels from seven (5-HT [5 min]) or 
four independent experiments (*P<0.01 5-HT [5 min] vs. basal; Mann-Whitney U test). 
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Figure 6. The 5-HT7 receptor increases cell surface expression of GluA1(Ser845) via protein 
kinase A in hippocampal neurones A: Representative immunoblots of hippocampal neurones 
treated with vehicle (Basal and 5-HT) SB258719 (10 µM) or H89 (10 µM) for 15 min 
followed by addition of 5-HT (1.0 µM) or vehicle (Basal) treatment for 5 min. B 
Quantification of pGluA1(Ser845) levels in total cell extracts and in cell surface fractions. 
Amount of proteins were normalised using GAPDH and pan-cadherin in the total extract and 
in the cell surface fraction, respectively. Values are expressed as fold increase ± SEM with 
respect to basal levels from seven (5-HT; *P<0.01 5-HT vs. basal, Mann-Whitney U test) or 
three independent experiments . 
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Figure 7. Iontophoretic administration of the 5-HT1A/7 receptor agonist 5-CT induced a 
predominant excitation in the baseline and AMPA-induced firing of hippocampal CA3 
pyramidal neurones in the presence of the 5-HT1A receptor antagonist WAY-100,635, in vivo. 
A: Group data revealed a mixed excitatory/inhibitory response to 5-CT administration on 
baseline neurone firing in the absence of WAY-100,635, which was modified to an almost 
exclusively excitatory response during 5-HT1A receptor blockade; neurone numbers are 
overlaid histograms of change in firing rate (in Hz). B: Similarly, in the absence of WAY-
100,635 5-CT application depressed AMPA-evoked firing, whereas in the presence of WAY-
100,635, 5-CT predominantly enhanced AMPA-evoked bursts of activity; neurone numbers 
are overlaid histograms of change in firing rate (in Hz). C-E: Typical examples of 5-CT 
inducing: an increase in baseline neuronal activity in the absence of WAY-100,635 (C); an 
increase in neuronal activity in the presence of WAY-100,635 (D); an enhancement of AMPA-
evoked firing in the presence of WAY-100,635, with demonstration of AMPA receptor 
mediation using NBQX also shown (E). * P<0.05 vs. basal levels; paired student’s t-test. 
  
  
This article is protected by copyright. All rights reserved. 
 
Figure 8. The 5-HT1A/7 receptor agonist 5-CT induced both enhancements and reductions in 
the amplitude of electrically-evoked AMPA-mediated EPSCs, in hippocampal CA3 
pyramidal neurones in the presence of the 5-HT1A receptor antagonist WAY-100,635, in vitro. 
Typical CA3 pyramidal neurone in which 5-CT induced a reduction (A) and an enhancement 
(B) in the magnitude of EPSCs, recorded in the presence of AP-5, Bicuculline, CGP55845 
and WAY-100,635, with typical traces during baseline, 5-CT, wash and NBQX shown, each 
trace is the average of 5 sweeps. C: Scatter plots representing EPSC amplitude over time of 
two CA3 pyramidal neurones in which 5-CT induced a reduction (top) and an enhancement 
(bottom), with the subsequent administration of NBQX also shown. D: Group data of the 
effect of 5-CT and NBQX on AMPA-mediated EPSC activity in the presence of WAY-
100,635; neurone numbers are overlaid histograms of change in EPSC amplitude as a 
percentage of baseline. * P<0.05 vs. basal levels; paired student’s t-test. 
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Figure 9. The 5-HT1A/7 receptor agonist 5-CT enhanced excitatory responses of hippocampal 
CA3 pyramidal neurons in vitro induced by short-term application of AMPA, in the presence 
of the 5-HT1A receptor antagonist and the sodium channel blocker, WAY-100,635 and 
tetrodotoxin, respectively. The 5-CT-induced enhancement was antagonized by the 5-HT7 
receptor antagonist, SB258719. A-C: CA3 pyramidal neurones recorded in current-clamp in 
the presence of WAY-100,635 and TTX demonstrating A: Repeatable AMPA perfusion-
induced depolarisations; B: The enhancement in AMPA responses induced by 5-CT and C: 
The reduced enhancement in the added presence of SB258719. D: Left: group data of the 
effect of 5-CT on the AMPA-evoked excitation of six CA3 pyramidal neurones, in the 
presence of WAY-100,635 and TTX and measured using area under the curve analysis. 
Right: group data of the normalised increase in AMPA-evoked responses induced by 5-CT in 
the absence and presence of SB258719 recorded from 3 of these neurons. E:  A CA3 
pyramidal neurone in which the effect of AMPA has been examined in the absence of WAY-
100-635 and TTX. ** P<0.05/0.01 vs. basal levels; paired student’s t-test. 
  
